

# 42 - References

## References

838 The Maudsley® Prescribing Guidelines in Psychiatry CHAPTER 10 References

1. Marrie RA, et al. The incidence and prevalence of psychiatric disorders in multiple sclerosis: a systematic review. *Mult Scler* 2015; 21:305–317.
2. Gottberg K, et al. A population-based study of depressive symptoms in multiple sclerosis in Stockholm county: association with functioning and sense of coherence. *J Neurol Neurosurg Psychiatry* 2007; 78:60–65.
3. Boeschoten RE, et al. Prevalence of depression and anxiety in multiple sclerosis: a systematic review and meta-analysis. *J Neurol Sci* 2017; 372:331–341.
4. Patten SB, et al. Depression in multiple sclerosis. *Int Rev Psychiatry* 2017; 29:463–472.
5. Kalb R, et al. Depression and suicidality in multiple sclerosis: red flags, management strategies, and ethical considerations. *Curr Neurol Neurosci Rep* 2019; 19:77.
6. Sadovnick AD, et al. Cause of death in patients attending multiple sclerosis clinics. *Neurology* 1991; 41:1193–1196.
7. Strupp J, et al. Risk factors for suicidal ideation in patients feeling severely affected by multiple sclerosis. *J Palliat Med* 2016; 19:523–528.
8. Sparaco M, et al. Psychiatric disorders in multiple sclerosis. *J Neurol* 2021; 268:45–60.
9. Corallo F, et al. A complex relation between depression and multiple sclerosis: a descriptive review. *Neurol Sci* 2019; 40:1551–1558.
10. Menculini G, et al. Psychiatric symptoms in multiple sclerosis: a biological perspective on synaptic and network dysfunction. *J Neurol Neurosurg Psychiatry* 2023; 94:389–395.
11. Moran PJ, et al. The validity of Beck Depression Inventory and Hamilton Rating Scale for Depression items in the assessment of depression among patients with multiple sclerosis. *J Behav Med* 2005; 28:35–41.
12. Pandya R, et al. Predictive value of the CES-D in detecting depression among candidates for disease-modifying multiple sclerosis treatment. *Psychosomatics* 2005; 46:131–134.
13. Minden SL, et al. Evidence-based guideline: assessment and management of psychiatric disorders in individuals with MS: report of the Guideline Development Subcommittee of the American Academy of Neurology. *Neurology* 2014; 82:174–181.
14. Rickards H. Depression in neurological disorders: Parkinson's disease, multiple sclerosis, and stroke. *J Neurol Neurosurg Psychiatry* 2005; 76 Suppl 1:i48–i52.
15. Silveira C, et al. Neuropsychiatric symptoms of multiple sclerosis: state of the art. *Psychiatry Investig* 2019; 16:877–888.
16. Patten SB. Current perspectives on co-morbid depression and multiple sclerosis. *Expert Rev Neurother* 2020; 20:867–874.

17. McIntosh GE, et al. Clinical practice guidelines for the detection and treatment of depression in multiple sclerosis: a systematic review. *Neurol Clin Pract* 2023; 13:e200154.
18. Mohr DC, et al. Comparative outcomes for individual cognitive-behavior therapy, supportive-expressive group psychotherapy, and sertraline for the treatment of depression in multiple sclerosis. *J Consult Clin Psychol* 2001; 69:942-949.
19. Ehde DM, et al. Efficacy of paroxetine in treating major depressive disorder in persons with multiple sclerosis. *Gen Hosp Psychiatry* 2008; 30:40-48.
20. Flax JW, et al. Effect of fluoxetine on patients with multiple sclerosis. *Am J Psychiatry* 1991; 148:1603.
21. Vollmer TL, et al. A randomized, double-blind, placebo-controlled trial of duloxetine for the treatment of pain in patients with multiple sclerosis. *Pain Pract* 2014; 14:732-744.
22. Hilty DM, et al. Psychopharmacology for neurologists: principles, algorithms, and other resources. *Continuum* 2006; 12:33-46.
23. Barak Y, et al. Treatment of depression in patients with multiple sclerosis. *Neurologist* 1998; 4:99-104.
24. Koch MW, et al. Pharmacologic treatment of depression in multiple sclerosis. *Cochrane Database Syst Rev* 2011; 2:CD007295.
25. Taylor D, et al. Pharmacological interventions for people with depression and chronic physical health problems: systematic review and meta- analyses of safety and efficacy. *Br J Psychiatry* 2011; 198:179-188.
26. Baghbanian SM, et al. The effects of bupropion on sexual dysfunction in female patients with multiple sclerosis: a double-blind randomized clinical trial. *Mult Scler Relat Disord* 2023; 69:104399.
27. Gil-Sanchez A, et al. Effects of vortioxetine on cognition and fatigue in patients with multiple sclerosis and depression: a case series study. *CNS Neurol Disord Drug Targets* 2024; 23:395-401.
28. Siegert RJ, et al. Depression in multiple sclerosis: a review. *J Neurol Neurosurg Psychiatry* 2005; 76:469-475.
29. Larcombe NA, et al. An evaluation of cognitive-behaviour therapy for depression in patients with multiple sclerosis. *Br J Psychiatry* 1984; 145:366-371.
30. Grossman P, et al. MS quality of life, depression, and fatigue improve after mindfulness training: a randomized trial. *Neurology* 2010; 75:1141-1149.
31. Shinto L, et al. Omega-3 fatty acids for depression in multiple sclerosis: a randomized pilot study. *PLoS One* 2016; 11:e0147195.
32. Schiffer RB, et al. Antidepressant pharmacotherapy of depression associated with multiple sclerosis. *Am J Psychiatry* 1990; 147:1493-1497.
33. Barak Y, et al. Moclobemide treatment in multiple sclerosis patients with comorbid depression: an open-label safety trial. *J Neuropsychiatry Clin Neurosci* 1999; 11:271-273.
34. Shkodina AD, et al. Pharmacological and non-pharmacological approaches for the management of neuropathic pain in multiple sclerosis. *CNS Drugs* 2024; 38:205-224.
35. Rasmussen KG, et al. Electroconvulsive therapy in patients with multiple sclerosis. *J ECT* 2007; 23:179-180.
36. Jones KH, et al. A large-scale study of anxiety and depression in people with multiple sclerosis: a survey via the web portal of the UK MS Register. *PLoS One* 2012; 7:e41910.
37. Korostil M, et al. Anxiety disorders and their clinical correlates in multiple sclerosis patients. *Mult Scler* 2007; 13:67-72.

38. Butler E, et al. 'It's the unknown' – understanding anxiety: from the perspective of people with multiple sclerosis. *Psychol Health* 2019; 34:368–383.

Drug treatment of psychiatric symptoms in the context of other conditions CHAPTER 10

39. Solaro C, et al. Pregabalin for treating paroxysmal painful symptoms in multiple sclerosis: a pilot study. *J Neurol* 2009; 256:1773–1774. 40. Bittner S, et al. [Pregabalin and gabapentin in multiple sclerosis: clinical experiences and therapeutic implications]. *Nervenarzt* 2011; 82:1273–1280. 41. Nabizadeh F, et al. Pseudobulbar affect in neurodegenerative diseases: a systematic review and meta-analysis. *J Clin Neurosci* 2022; 100:100–107. 42. Feinstein A, et al. The effects of anxiety on psychiatric morbidity in patients with multiple sclerosis. *Mult Scler* 1999; 5:323–326. 43. Feinstein A, et al. Prevalence and neurobehavioral correlates of pathological laughing and crying in multiple sclerosis. *Arch Neurol* 1997; 54:1116–1121. 44. Andersen G, et al. Citalopram for post-stroke pathological crying. *Lancet* 1993; 342:837–839. 45. Robinson RG, et al. Pathological laughing and crying following stroke: validation of a measurement scale and a double-blind treatment study. *Am J Psychiatry* 1993; 150:286–293. 46. Burns A, et al. Sertraline in stroke-associated lability of mood. *Int J Geriatr Psychiatry* 1999; 14:681–685. 47. Johnson B, et al. Crying and suicidal, but not depressed. Pseudobulbar affect in multiple sclerosis successfully treated with valproic acid: case report and literature review. *Palliat Support Care* 2015; 13:1797–1801. 48. Piro EP, et al. Dextromethorphan plus ultra low-dose quinidine reduces pseudobulbar affect. *Ann Neurol* 2010; 68:693–702. 49. McGrane I, et al. Treatment of pseudobulbar affect with fluoxetine and dextromethorphan in a woman with multiple sclerosis. *Ann Pharmacother* 2017; 51:1035–1036. 50. Joseph B, et al. Prevalence of bipolar disorder in multiple sclerosis: a systematic review and meta-analysis. *Evid Based Ment Health* 2021; 24:88–94. 51. Patten SB, et al. Biopsychosocial correlates of lifetime major depression in a multiple sclerosis population. *Mult Scler* 2000; 6:115–120. 52. Davids E, et al. Antipsychotic treatment of psychosis associated with multiple sclerosis. *Prog Neuropsychopharmacol Biol Psychiatry* 2004; 28:743–744. 53. Budur K, et al. Olanzapine for corticosteroid-induced mood disorders. *Psychosomatics* 2003; 44:353. 54. Camara-Lemarrroy CR, et al. The varieties of psychosis in multiple sclerosis: a systematic review of cases. *Mult Scler Relat Disord* 2017; 12:9–14. 55. Jefferies K. The neuropsychiatry of multiple sclerosis. *Adv Psychiatric Treat* 2006; 12:214–220. 56. Narita Z, et al. Possible effects of electroconvulsive therapy on refractory psychosis in primary progressive multiple sclerosis: a case report. *Neuropsychopharmacol Rep* 2018; 38:92–94. 57. Stamoula E, et al. Atypical antipsychotics in multiple sclerosis: a review of their in vivo immunomodulatory effects. *Mult Scler Relat Disord* 2022; 58:103522. 58. Aragona M, et al. Psychopathological and cognitive effects of therapeutic cannabinoids in multiple sclerosis: a double-blind, placebo controlled, crossover study. *Clin Neuropharmacol* 2009; 32:41–47. 59. Black N, et al. Cannabinoids for the treatment of mental disorders and symptoms of mental disorders: a systematic review and meta-analysis. *Lancet Psychiatry* 2019; 6:995–1010. 60. Pierson SH, et al. Treatment of cognitive impairment in multiple sclerosis. *Behav Neurol* 2006; 17:53–67. 61. Krupp LB, et al. Donepezil improved memory in multiple sclerosis in a randomized clinical trial. *Neurology* 2004; 63:1579–1585. 62. Greene YM, et al. A 12-week, open trial of donepezil hydrochloride in patients with multiple sclerosis and associated cognitive impairments. *J Clin Psychopharmacol* 2000; 20:350–356. 63. Krupp LB, et al. Multicenter randomized clinical trial of donepezil for memory impairment in multiple sclerosis. *Neurology* 2011; 76:1500–1507. 64. Lovera JF, et al. Memantine for cognitive impairment in multiple sclerosis: a randomized placebo-controlled trial. *Mult Scler* 2010; 16:715–723. 65. Chen MH, et al. Cognitive efficacy of pharmacologic treatments in multiple sclerosis: a systematic review. *CNS Drugs* 2020; 34:599–628. 66. Patti F. Treatment of cognitive impairment in patients with

multiple sclerosis. *Expert Opin Investig Drugs* 2012; 21:1679–1699. 67. Bakshi R. Fatigue associated with multiple sclerosis: diagnosis, impact and management. *Mult Scler* 2003; 9:219–227. 68. Sepulcre J, et al. Fatigue in multiple sclerosis is associated with the disruption of frontal and parietal pathways. *Mult Scler* 2009; 15:337–344. 69. Ormstad H, et al. Chronic fatigue and depression due to multiple sclerosis: immune-inflammatory pathways, tryptophan catabolites and the gut-brain axis as possible shared pathways. *Mult Scler Relat Disord* 2020; 46:102533. 70. Van KK, et al. A randomized controlled trial of cognitive behavior therapy for multiple sclerosis fatigue. *Psychosom Med* 2008; 70:205–213. 71. Pucci E, et al. Amantadine for fatigue in multiple sclerosis. *Cochrane Database Syst Rev* 2007; 1:CD002818. 72. National Institute for Health and Care Excellence. Multiple sclerosis in adults: management. NICE guideline [NG220]. 2022 (last checked May 2024); <https://www.nice.org.uk/guidance/ng220>. 73. Yang TT, et al. Pharmacological treatments for fatigue in patients with multiple sclerosis: a systematic review and meta-analysis. *J Neurol Sci* 2017; 380:256–261. 74. Perez DQ, et al. Efficacy and safety of amantadine for the treatment of fatigue in multiple sclerosis: a systematic review and meta-analysis. *Neurodegener Dis Manag* 2020; 10:383–395. 75. Shangyan H, et al. Meta-analysis of the efficacy of modafinil versus placebo in the treatment of multiple sclerosis fatigue. *Mult Scler Relat Disord* 2018; 19:85–89. 76. Davies M, et al. Safety profile of modafinil across a range of prescribing indications, including off-label use, in a primary care setting in England: results of a modified prescription-event monitoring study. *Drug Saf* 2013; 36:237–246. 77. López-Muñoz P, et al. Effect of vitamin D supplementation on fatigue in multiple sclerosis: a systematic review and meta-analysis. *Nutrients* 2023; 15:2861.

---

Revision #1

Created 2026-01-04 20:17:50 UTC by Omar Ayman

Updated 2026-01-04 20:17:50 UTC by Omar Ayman